for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Transcode Therapeutics Inc

RNAZ.OQ

Latest Trade

2.75USD

Change

-0.17(-5.82%)

Volume

12,072

Today's Range

2.66

 - 

2.96

52 Week Range

2.36

 - 

7.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.92
Open
2.96
Volume
12,072
3M AVG Volume
82.85
Today's High
2.96
Today's Low
2.66
52 Week High
7.00
52 Week Low
2.36
Shares Out (MIL)
12.90
Market Cap (MIL)
34.71
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

TransCode Therapeutics Reports Q3 Loss Per Share $0.20

TransCode Therapeutics Reports Business Progress And Second Quarter 2021 Financial Results

Transcode Therapeutics Inc Awarded Funding From National Institutes Of Health

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Transcode Therapeutics Inc

TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer. TTX-MC138 comprises proprietary iron-oxide nanoparticles and oligonucleotides that specifically target microRNA-10b. The nanoparticles serve as the vehicle to deliver oligonucleotides to metastatic cancer cells. The magnetic properties of these nanoparticles allow for monitoring of their delivery using non-invasive imaging. Its pipeline products also include TTX-siPDL1, TTX-siLIN28b and TTX-RIGA. TTX-siPDL1 is a checkpoint inhibitor targeting programmed cell death protein ligand 1 (PD-L1). TTX-RIGA utilizes its delivery system and is intended to activate the RIG-I signaling pathway to elicit an immune response to eliminate and/or reduce the risk of developing disorders associated with abnormal apoptotic or differentiative processes, by triggering an immune response that targets developing cancer cells.

Industry

Business Services

Contact Info

6 Liberty Square, #2382

BOSTON, MA

02109

United States

+1.857.3016857

https://www.transcodetherapeutics.com/

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up